GGrantIndex
← Leaderboards

Timothy R Donahue

University Of California Los Angeles

$4,604,839
Attributed
$12,773,301
Total exposure
6
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY201425
$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,773,301 · 6

By mechanism

R01$10,217,212 · 4
U01$2,377,645 · 1
T32$178,444 · 1

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Pancreatic Ductal Adenocarcinoma

Research focus

Pancreatic Ductal AdenocarcinomaMetabolismMalignant Neoplasm Of PancreasMalignant NeoplasmsTumorResistanceMass Spectrum AnalysisNeoplastic CellPathway InteractionsMetabolicTumor MicroenvironmentMediatingSignal TransductionNucleotide MetabolismMouse ModelProductionClinical TrialsPancreatic Ductal Adenocarcinoma ModelSolid NeoplasmUptakeResponsePreventImmune Checkpoint BlockadeNucleotides

Grant awards (25)

Causes and Consequences of Adenosine Signaling in Pancreatic Cancer$653,625
R01 · FY2025 · CA · contact PI
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$585,317
R01 · FY2025 · CA
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$572,887
R01 · FY2025 · CA · contact PI
UCLA Surgeon-Scientist Basic Cancer Research Training Program (UCLA Surgeon-Scientist BCRTP)$178,444
T32 · FY2025 · CA · contact PI
Causes and Consequences of Adenosine Signaling in Pancreatic Cancer$653,452
R01 · FY2024 · CA · contact PI
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$575,892
R01 · FY2024 · CA · contact PI
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$567,204
R01 · FY2024 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$590,100
R01 · FY2023 · CA
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$565,439
R01 · FY2023 · CA · contact PI
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$48,151
R01 · FY2023 · CA · contact PI
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$607,124
R01 · FY2022 · CA
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$602,783
R01 · FY2022 · CA · contact PI
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$96,857
R01 · FY2022 · CA · contact PI
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer$634,454
R01 · FY2021 · CA
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer$630,802
R01 · FY2021 · CA · contact PI
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer$433,388
U01 · FY2019 · CA
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$585,018
R01 · FY2018 · CA
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer$459,169
U01 · FY2018 · CA
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$585,018
R01 · FY2017 · CA
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer$476,683
U01 · FY2017 · CA
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$585,018
R01 · FY2016 · CA
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer$495,258
U01 · FY2016 · CA
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$559,454
R01 · FY2015 · CA
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer$513,147
U01 · FY2015 · CA
PET Imaging-guided Personalized Therapy in Pancreatic Cancer$518,617
R01 · FY2014 · CA